BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 6118745)

  • 1. Etretinate in bowenoid papulosis.
    Blanchet-Bardon C; Puissant A; Lutzner M
    Lancet; 1981 Dec; 2(8259):1348-9. PubMed ID: 6118745
    [No Abstract]   [Full Text] [Related]  

  • 2. Etretinate in bowenoid papulosis.
    De Mari F; Rampen FH; van Everdingen JJ
    Lancet; 1981 Oct; 2(8252):936-7. PubMed ID: 6117716
    [No Abstract]   [Full Text] [Related]  

  • 3. Etretinate in bowenoid papulosis.
    de Mari F; Rampen FH; van Everdingen JJ
    Lancet; 1982 May; 1(8279):1027. PubMed ID: 6122841
    [No Abstract]   [Full Text] [Related]  

  • 4. Etretinate (Tigason) for skin disease.
    Drug Ther Bull; 1983 Feb; 21(3):9-11. PubMed ID: 6839967
    [No Abstract]   [Full Text] [Related]  

  • 5. [Aromatic retinoid in dermatology].
    Notowicz A; Vermeiden I; Stolz E
    Ned Tijdschr Geneeskd; 1980 Aug; 124(31):1284-6. PubMed ID: 7412900
    [No Abstract]   [Full Text] [Related]  

  • 6. Retinoids in dermatology.
    Lancet; 1981 Mar; 1(8219):537-8. PubMed ID: 6111638
    [No Abstract]   [Full Text] [Related]  

  • 7. [Aromatic retinoids, a new therapy in dermatology].
    de la Brassinne M; Lapière CM
    Rev Med Liege; 1982 May; 37(9):356-9. PubMed ID: 7100713
    [No Abstract]   [Full Text] [Related]  

  • 8. [Oral retinoid therapy in dermatoses].
    Török L; Reszler M; Egyedi K; Raffai S
    Orv Hetil; 1982 Apr; 123(14):845-8. PubMed ID: 7043355
    [No Abstract]   [Full Text] [Related]  

  • 9. A randomized trial of etretinate (Tigason) in palmoplantar pustulosis.
    Foged E; Holm P; Larsen PO; Laurberg G; Reymann F; Roesdahle K; Ullman S
    Dermatologica; 1983; 166(4):220-3. PubMed ID: 6343149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Possible use of retinoids in the prevention and therapy of epithelial tumors].
    Fantoli U
    Recenti Prog Med; 1981 May; 70(5):559-60. PubMed ID: 7031803
    [No Abstract]   [Full Text] [Related]  

  • 11. [Etretinat (Tigason). A vitamin A acid derivative for peroral treatment of hyperkeratotic dermatoses].
    Foged EK; Laurberg G; Schmidt H
    Ugeskr Laeger; 1983 Jun; 145(23):1797-9. PubMed ID: 6879814
    [No Abstract]   [Full Text] [Related]  

  • 12. Intractable skin disorders treated with the aromatic retinoid etretinate (Tigason). Two and a half years' experience in the Transvaal.
    Findlay GH
    S Afr Med J; 1983 Jul; 64(2):54-6. PubMed ID: 6867876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic evaluation of the oral retinoid Ro 10-9359 in several non-psoriatic dermatoses.
    Viglioglia PA
    Br J Dermatol; 1980 Nov; 103(5):483-7. PubMed ID: 7437314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of etretinate (Tigason) in clearing and prevention of relapse of palmoplantar pustulosis.
    Lassus A; Lauharanta J; Juvakoski T; Kanerva L
    Dermatologica; 1983; 166(4):215-9. PubMed ID: 6343148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etretinate. A review of its pharmacological properties and therapeutic efficacy in psoriasis and other skin disorders.
    Ward A; Brogden RN; Heel RC; Speight TM; Avery GS
    Drugs; 1983 Jul; 26(1):9-43. PubMed ID: 6224672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retinoid concentrations in skin, serum and adipose tissue of patients treated with etretinate.
    Rollman O; Vahlquist A
    Br J Dermatol; 1983 Oct; 109(4):439-47. PubMed ID: 6226308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tolerability of an aromatic retinoid (RO 10 9359, etretinate, Tigason, Roche). Research on its toxicity on hematopoietic, renal and thyroid functions. Interactions with the metabolism of natural retinoids].
    Fontan B; Bonafé JL; Moatti JP
    Ann Dermatol Venereol; 1983; 110(1):23-31. PubMed ID: 6859752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Indications for retinoids].
    Kint A
    Verh K Acad Geneeskd Belg; 1983; 45(5):403-13. PubMed ID: 6583889
    [No Abstract]   [Full Text] [Related]  

  • 19. Persistent etretinate levels in plasma after changing the therapy to acitretin.
    Lambert WE; De Leenheer AP; De Bersaques JP; Kint A
    Arch Dermatol Res; 1990; 282(5):343-4. PubMed ID: 2145814
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of retinoids on natural killer cell activity.
    Pigatto PD; Bersani L; Colotta F; Morelli M; Altomare GF; Polenghi MM
    Arch Dermatol Res; 1986; 278(6):507-9. PubMed ID: 3466579
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.